Latanoprost

Latanoprost
Clinical data
Trade names	Xalatan, others
AHFS/Drugs.com	Monograph
MedlinePlus	a697003
License data	US DailyMed: Latanoprost;
Pregnancy; category	AU: B3;
Routes of; administration	Topical eye drop
ATC code	S01EE01 (WHO) S01EE51 (WHO), S01EE52 (WHO);
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Metabolism	Activation by ester hydrolysis, deactivation by beta oxidation
Onset of action	3–4 hours
Elimination half-life	17 minutes (plasma)
Duration of action	≥ 24 hours
Excretion	Mainly via kidney
Identifiers
	IUPAC name Isopropyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2- [(3R)3-hydroxy-5-phenylpentyl]-cyclopentyl] hept-5-enoate;
CAS Number	130209-82-4 ;
PubChem CID	5311221;
IUPHAR/BPS	1961;
DrugBank	DB00654 ;
ChemSpider	4470740 ;
UNII	6Z5B6HVF6O;
KEGG	D00356 ;
ChEBI	CHEBI:6384 ;
ChEMBL	ChEMBL1051 ;
CompTox Dashboard (EPA)	DTXSID1041057 ;
ECHA InfoCard	100.162.178
Chemical and physical data
Formula	C26H40O5
Molar mass	432.601 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(OC(C)C)CCC/C=C\C[C@H]2[C@@H](O)C[C@@H](O)[C@@H]2CC[C@@H](O)CCc1ccccc1;
	InChI InChI=1S/C26H40O5/c1-19(2)31-26(30)13-9-4-3-8-12-22-23(25(29)18-24(22)28)17-16-21(27)15-14-20-10-6-5-7-11-20/h3,5-8,10-11,19,21-25,27-29H,4,9,12-18H2,1-2H3/b8-3-/t21-,22+,23+,24-,25+/m0/s1 ; Key:GGXICVAJURFBLW-CEYXHVGTSA-N ;
	(verify)

Latanoprost, sold under the brand name Xalatan among others, is a medication used to treat increased pressure inside the eye (intraocular pressure). This includes ocular hypertension and open-angle glaucoma. Latanaprost is applied as eye drops to the eyes. Onset of effects is usually within four hours, and they last for up to a day.

Common side effects include blurry vision, redness of the eye, itchiness, and darkening of the iris. Latanoprost is in the prostaglandin analogue family of medications. It works by increasing the outflow of aqueous fluid from the eyes through the uveoscleral tract.

Latanoprost was approved for medical use in the United States and the European Union in 1996. It is on the World Health Organization's List of Essential Medicines. Latanoprost is available as a generic medication. In 2022, it was the 67th most commonly prescribed medication in the United States, with more than 9 million prescriptions. It is available as a fixed-dose combination with netarsudil as netarsudil/latanoprost and with timolol as latanoprost/timolol.